Macquarie Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Macquarie Group’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,058	Closed	-$27K	–	2184
2022 Q3	$27K	Hold	2,058	–	–	﹤0.01%	2119
2022 Q2	$26K	Hold	2,058	–	–	﹤0.01%	2236
2022 Q1	$31	Hold	2,058	–	–	﹤0.01%	2295
2021 Q4	$36K	Hold	2,058	–	–	﹤0.01%	2263
2021 Q3	$43K	Buy	+2,058	New	+$45.3K	﹤0.01%	2275

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group's NGM Position: Q4 2022 in Review

Macquarie Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2022, closing a stake of 2,058 shares — an estimated $27K sold.

Macquarie Group first reported a position in NGM in Q3 2021 and held it in 5 quarters. The position peaked at $43K in Q3 2021. 125 funds tracked by Wall St. Rank hold NGM as of Q4 2022.

Macquarie Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Macquarie Group sold 2,058 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $27K.
Macquarie Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
Macquarie Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $43K in Q3 2021.
125 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.